VCYT Veracyte Diagnostics: Accounting Value per Share

This chart reflects that the asset value of Veracyte, Inc. (VCYT), which specializes in high-precision oncology diagnostics, currently stands at 17.13. Mark Staple is effectively integrating innovative screenings into global practice, supported by rigorous operational control. The business is protected by patents for AI solutions and complex FDA certification, while an impeccable image as a scientific pioneer ensures full confidence from the professional medical community.

Veracyte Inc (VCYT) - Accounting Value per Share from 07/04/2022 to 10/27/2026

Summary analytical data breakdowns for veracyte.com (VCYT)

- price and consensus price forecast:

Stock Quotes Veracyte Corp|VCYT - Average Forecast Price

- market capitalization data:

Market Valuation Veracyte, Inc.|VCYT - Aggregate Business Value

- book capitalization data:

Book Value per Share Veracyte|VCYT - Company Net Assets|Market Capitalization to Book Value Ratio veracyte.com|VCYT - Company Total Assets

- debt and liquidity data:

Debt to Equity Veracyte, Inc.|VCYT - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Veracyte|VCYT - Company Total Debt|Debts to Book Capitalization Veracyte, Inc.

Analysis of all company metrics:Veracyte Corp, VCYT

Selecting stocks with a high margin of safety begins with an assessment of equity. This indicator is calculated as the difference between all company assets and liabilities, divided by the number of shares. For Veracyte, Inc. (VCYT), this metric reflects the integration efficiency of European laboratories and M&A transactions. Growth in net asset value confirms successful business expansion. By analyzing the book value per common share trend, an investor can see the company's actual tangible asset base.

Competitor analysis for Veracyte, Inc.